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Purpose/Objective: Hypoxia is an important parameter 
influencing tumor progression and treatment efficacy in head 
and neck (HN) cancer. [18F]HX4 is a hypoxia PET tracer for 
the detection and quantification of tumor hypoxia. The aim 
of this study was first to investigate the test-retest 
repeatability of HX4 PET imaging and second to evaluate 
changes in spatio-temporal uptake of HX4 during 
radiotherapy.  
Materials and Methods: 10 HN cancer patients 
(NCT01075399) were included in the repeatability analysis. In 
these patients two sequential pre-treatment HX4 PET/CT 
scans were acquired within one week without any cancer 
treatment. Next, for 17 HN patients of an ongoing study 
(NCT01347281) HX4 PET images were acquired both before 
treatment and during the second week of radiotherapy 
(21±2Gy delivered). The maximum and mean standardized 
uptake values (SUVmax and SUVmean) of HX4 in the tumor were 
determined. In addition, the tumor-to-background ratio 
(TBRmax) was calculated. For the repeatability data-set, a 
Bland-Altman analysis was performed providing the mean 
difference in SUV uptake (mean ΔSUV) and a 95% confidence 
interval presented as an upper and lower limit of agreement. 
These limits were used to evaluate the change in spatial 
uptake stability of the hypoxia scans during radiotherapy. 
PET/CT images were registered and a voxel-wise comparison 
of the uptake was performed, providing a correlation 
coefficient.  
Results: A significant strong linear correlation of HX4 uptake 
between both pre-treatment scans was observed for all 
parameters: SUVmax (r=0.91, p<0.001), SUVmean (r=0.96, 
p<0.001), TBRmax (r=0.94, p<0.001). The relative differences 
were -3%±13% (SUVmax), -4%±8% (SUVmean) and 7%±16% 
(TBRmax). The voxel-wise analysis of the spatial uptake 
pattern within the tumor provided also a strong correlation 
(R=0.61±0.20). The upper and lower limit of agreement were 
and SUV of 0.20±0.07 and -0.13±0.10, respectively. This 
shows that also on a voxel level the SUV values are stable 
between both measurements. During radiotherapy a 
treatment effect larger than the test-retest repeatability was 
observed: significant decrease of SUVmean (-9±20%; p=0.01), 
SUVmax (-16±23; p=0.001) and TMRmax (-19±16%; p<0.001). 
Assessment of the spatiotemporal stability of the HX4 uptake 
before and during treatment provided an average correlation 
of 0.57±0.19, indicating in general a good spatiotemporal 
stability comparable to the test-retest study.  
 
 
Conclusions: Hypoxia PET imaging using HX4 provides reliable 
and repeatable results for patients with head and neck 
cancer. Repeated HX4 PET imaging to assess the hypoxic 
status of tumors before and during treatment shows a 
reduction in hypoxia larger than the test-retest repeatability, 
although the pattern of hypoxia on a voxel level remains 
similar. This opens strategies to guide hypoxia targeted 
treatments including hypoxia-specific drugs and radiation 
dose-painting.  
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Purpose/Objective: Neoadjuvant chemoradiotherapy (nCRT) 
can induce significant tumor downstaging before surgery, 
even resulting in a pathologic complete response (pathCR) in 
approximately 30% of patients. It is speculated that surgery 
might be safely omitted in this selected group of patients 
with a complete response. On the other hand, patients with a 
poor pathologic response to nCRT may benefit less from nCRT 
but are exposed to its toxicity. The aim of this study was to 
explore the value of diffusion-weighted magnetic resonance 
imaging (DW-MRI) for the prediction of response to nCRT in 
patients with esophageal cancer. 
Materials and Methods: This prospective study was approved 
by our institutional review board and patients provided 
written informed consent. Twenty patients presented at our 
center from May 2013 until May 2014 with newly diagnosed 
esophageal cancer that were planned to receive nCRT 
followed by surgery were included. Patients underwent MRI 
scanning with DW-MRI sequences within two weeks before 
nCRT (MRIpre), after 8-13 fractions (MRIduring), and three to 
nine weeks after completion of nCRT, prior to surgery 
(MRIpost). Transverse DW-MR images were acquired using three 
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different diffusion-sensitizing gradients (b = 0, 200 and 800 
s/mm2). The median tumor apparent diffusion coefficient 
(ADC) was determined at the three time points. The 
predictive potential of initial ADC, and change in ADC (ΔADC) 
during and after treatment for pathologic complete response 
(pathCR) and good response (GR) was assessed. Good 
response was defined as pathCR or near-pathCR (tumor 
regression grade [TRG] 1 or 2).  
Results: A pathCR after nCRT was found in 4 of 20 patients 
(20%), and 8 patients (40%) showed a good response. The 
ΔADCduring was significantly higher in pathCR patients 
compared to patients without pathCR, as well as in good 
responders compared to poor responders (Table 1, Figure 1-
3). Initial tumor ADC and ΔADCpost were not significantly 
related to pathologic response. ROC analysis for ΔADCduring 
resulted in an area under the curve (AUC) of 0.90 for 
discriminating pathCR from no pathCR at an optimal cut-off 
value of 28.9% (sensitivity 100%, specificity 75%, accuracy 
95%, PPV 94%, and NPV 100%). For discriminating good from 
poor responders, ΔADCduring showed an AUC of 0.92 with an 
optimal cut-off value of 20.7% (sensitivity 82%, specificity 
100%, accuracy 89%, PPV 100%, and NPV 80%).  
 
 
 
 
Conclusions: The treatment-induced change in ADC as 
determined on DW-MRI during the first 2-3 weeks of nCRT for 
esophageal cancer allows for accurate early prediction of 
pathologic response. The high sensitivity and NPV of 
ΔADCduring for predicting residual cancer are particularly 
promising when considering a patient-tailored wait-and-see 
approach with omission of surgery in the future. The high 
specificity and PPV of ΔADCduring for predicting poor response 
are promising for future considerations regarding 
modification or discontinuation of nCRT early during 
treatment.  
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Purpose/Objective: The purpose of the current study was to 
investigate the ability of pre-treatment factors and response 
signals extracted from standard CBCT images obtained during 
fractionated radiotherapy to predict the lung 
radioresponsiveness (LuRa) measured as density changes in 
follow-up CT scans for NSCLC patients. 
Materials and Methods: Follow-up CT scans acquired within 6 
months after commencement of radiotherapy (RT) were 
evaluated for 135 NSCLC patients treated with CBCT image 
guided RT to 60 or 66 Gy in 2 Gy fractions. Dose-effect curves 
were produced from follow-up CT scans by relating changes 
in regional lung density to regional planned dose using 
deformable image registration. LuRa was defined as the slope 
of a linear fit to the dose-effect curve and provides an 
objective measure of the patients' individual susceptibility to 
radiation. Cone beam signals (CBS) were obtained by 
analysing changes in lung density in CBCT images acquired 
during the treatment course. The association of LuRa with 
pre-treatment factors and CBS was investigated in terms of 
overall correlations and for the ability to predict subgroups of 
patients with high or low responsiveness. 
Results: LuRa values range from -1.1 to 6.2 HU/Gy with a 
median at 1.0 HU/Gy. Of the pre-treatment factors, age 
correlated most with LuRa on univariable analysis (R=0.31). 
CBS obtained at the 20th and 30th treatment fraction was 
significantly correlated with LuRa (R=0.19 and R=0.34, 
respectively), while the signal obtained at the 10th fraction 
only reached borderline significance (R=0.16, p=0.068). Age 
and CBS extracted at 10th, 20th, and 30th treatment fraction 
were significant in multivariable analysis and a set of models 
for predicting LuRa based on these parameters were 
established (see table). Due to the low correlations, the 
models might have limited clinical impact. However, for 
typical treatments ~15% of the patients experience a grade 
3+ pneumonitis, and the right-sided tail of the LuRa values 
contains ~15% of the data as well. Thus, a dichotomization of 
the LuRa values at 85% (2.7 HU/Gy) might be clinically 
relevant. The ability of the 10th fraction model to predict a 
low response in patients is visualized as ROC curves in the 
figure. For safe dose escalation, all high-responsive patients 
must be classified correctly. In this regime (specificity=1), 
the full model classified significantly more of the low-
responsive patients correctly than the model only including 
age (58% vs. 36%, p<0.001). 
 
